Ratbi Ilham, Legendre Marie, Niel Florence, Martin Josiane, Soufir Jean-Claude, Izard Vincent, Costes Bruno, Costa Catherine, Goossens Michel, Girodon Emmanuelle
Service de Biochimie et Génétique Moléculaire, AP-HP et INSERM U841, IMRB, eq 21, Hôpital Henri-Mondor, Créteil, France.
Hum Reprod. 2007 May;22(5):1285-91. doi: 10.1093/humrep/dem024. Epub 2007 Feb 28.
Mutations in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene have been widely detected in infertile men with congenital bilateral absence of the vas deferens (CBAVD). Despite extensive analysis of the CFTR gene using varied screening methods, a number of cases remain unsolved and could be attributable to the presence of large gene rearrangements, as recently shown for CF patients.
We carried out a complete CFTR gene study in a group of 222 CBAVD patients with strict diagnosis criteria and without renal anomaly, and searched for rearrangements using a semi-quantitative assay in a subgroup of 61 patients.
The overall mutation detection rate was 87.8%, and 82% of patients carried two mutations. Ten out of the 99 different mutations accounted for 74.6% of identified alleles. Four large rearrangements were found in patients who already carried a mild mutation: two known partial deletions (exons 17a to 18 and 22 to 23), a complete deletion and a new partial duplication (exons 11 to 13). The rearrangements accounted for 7% of the previously unknown alleles and 1% of all identified alleles.
Screening for rearrangements should be part of comprehensive CFTR gene studies in CBAVD patients and may have impacts on genetic counselling for the patients and their families.
在先天性双侧输精管缺如(CBAVD)的不育男性中已广泛检测到囊性纤维化(CF)跨膜传导调节因子(CFTR)基因突变。尽管使用多种筛查方法对CFTR基因进行了广泛分析,但仍有一些病例未得到解决,这可能归因于大基因重排的存在,正如最近在CF患者中所显示的那样。
我们对一组222例诊断标准严格且无肾脏异常的CBAVD患者进行了完整的CFTR基因研究,并在61例患者的亚组中使用半定量检测方法寻找重排。
总体突变检出率为87.8%,82%的患者携带两个突变。99种不同突变中的10种占已鉴定等位基因的74.6%。在已经携带轻度突变的患者中发现了4种大的重排:两种已知的部分缺失(外显子17a至18和22至23)、一种完全缺失和一种新的部分重复(外显子11至13)。这些重排在先前未知的等位基因中占7%,在所有已鉴定的等位基因中占1%。
重排筛查应成为CBAVD患者CFTR基因综合研究的一部分,可能会对患者及其家庭的遗传咨询产生影响。